

PERCHERON THERAPEUTICS TO PRESENT AT AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) ANNUAL MEETING

Melbourne, Australia – 19 February 2026: Percheron Therapeutics Limited (ASX: PER) ('the Company'), an international biotechnology company focused on the development of novel therapies for oncology and rare diseases, is pleased to advise that it has had an abstract accepted for presentation at the Annual Meeting of the American Association of Cancer Research (AACR), to be held in San Diego, CA, from 17 – 22 April 2026.

The AACR Annual Meeting is one of the most important scientific conferences in cancer research. The 2025 meeting attracted more than 22,000 attendees from 85 countries and territories. In addition to the world's foremost oncology researchers, the conference is attended by delegates from pharmaceutical companies and investors and has become a valuable forum for companies to share new data and results.

Percheron's abstract principally discusses the results of the recently completed phase I study of HMBD-002 in patients with advanced cancer. The Company looks forward to sharing full results at the time of the conference, in accordance with AACR's embargo policies.

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated, and Percheron aims to commence further clinical trials in CY2026.

For more information, please contact info@PercheronTx.com.

This announcement has been authorized for release to the Australian Securities Exchange by the Board of Directors.
